Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Marginal zone lymphoma (MZL) is challenging to treat, with many patients relapsing following initial treatment. We report the long-term efficacy and safety of copanlisib, a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, in the subset of 23 patients with relapsed/refractory MZL treated in th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Panayiotidis, Panayiotis, Follows, George A., Mollica, Luigina, Nagler, Arnon, Özcan, Muhit, Santoro, Armando, Stevens, Don, Trevarthen, David, Hiemeyer, Florian, Garcia-Vargas, Jose, Childs, Barrett H., Zinzani, Pier Luigi, Dreyling, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7876879/
https://ncbi.nlm.nih.gov/pubmed/33560394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002910
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados